Drug intelligence / Profile preview

ALZ-507

Development stage: Unknown
Lead developer: Alzheon
Modality: Small Molecules
Administration: Oral

Overview

ALZ-507 is an orally administered small molecule drug being developed by Alzheon for the treatment of Alzheimer's disease. It is designed as a next-generation follow-on to Alzheon's lead candidate, valiltramiprosate (ALZ-801). ALZ-507 targets upstream amyloid aggregation to inhibit the formation of neurotoxic soluble amyloid oligomers, which are considered key drivers of Alzheimer's pathology. Additionally, the drug incorporates an APOE4 corrector mechanism of action, potentially enhancing its anti-oligomer effects. Developed for once-daily oral administration, ALZ-507 aims to provide improved gastrointestinal tolerability and a favorable safety profile. It is currently in Phase 1 clinical development.

Targets

APOE4 (Apolipoprotein E4)

Beyond the preview

Go deeper on ALZ-507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALZ-507.

Explore the full profile